Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Core Viewpoint - Sharps Technology, Inc. is enhancing its manufacturing capacity through a $35 million acquisition, positioning itself in the specialized copolymer prefillable syringe (PFS) system industry in the U.S. This move is expected to generate over $200 million in product orders within the first five years of operation [1][2]. Acquisition Details - The acquisition involves the purchase of InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina, which will be the only fully dedicated COC prefillable syringe manufacturing plant in North America [1][4]. - The asset acquisition price is $35 million, with an assumption of related liabilities up to $4 million [4]. Sales Agreement - Sharps has signed a 5-year, $200 million syringe Sales Agreement with Nephron Pharmaceuticals for copolymer prefillable syringes, with product deliveries expected to begin in late Q2 of 2025 [1][3]. - The agreement includes minimum orders for next-generation copolymer prefillable 10 mL and 50 mL syringes, as well as 10 mL SoloGard polypropylene syringes [3]. Revenue Projections - The projected revenue from the new syringe sales is approximately $37 million for the first 12 months of sales, with total revenue expected to exceed $200 million over the five-year agreement [1][3]. - The company anticipates significant short and long-term revenue growth from this transaction, entering a highly profitable market segment [2]. Manufacturing Capabilities - The new facility will feature state-of-the-art, fully automated manufacturing, packaging, and distribution capabilities, designed to meet the high demand for specialty syringe systems [4]. - Sharps currently operates a manufacturing facility in Hungary and is expanding its capacity in the U.S. through this acquisition [5].